These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24041919)

  • 1. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.
    Higgins GA; Sellers EM; Fletcher PJ
    Trends Pharmacol Sci; 2013 Oct; 34(10):560-70. PubMed ID: 24041919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders.
    Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1071-88. PubMed ID: 25870913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
    Miller KJ; Wacker DA
    Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of lorcaserin in the management of obesity.
    Hess R; Cross LB
    Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of impulsivity and reward in the anti-obesity actions of 5-HT
    Higgins GA; Zeeb FD; Fletcher PJ
    J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 5-HT
    Higgins GA; Brown M; St John J; MacMillan C; Silenieks LB; Thevarkunnel S
    Neuropharmacology; 2020 Jun; 170():108064. PubMed ID: 32222404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine.
    Zeeb FD; Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1231-40. PubMed ID: 25781911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
    Higgins GA; Fletcher PJ; Shanahan WR
    Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.
    Shram MJ; Schoedel KA; Bartlett C; Shazer RL; Anderson CM; Sellers EM
    Clin Pharmacol Ther; 2011 May; 89(5):683-92. PubMed ID: 21412231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACS chemical neuroscience molecule spotlight on Lorcaserin.
    Hopkins CR
    ACS Chem Neurosci; 2010 Nov; 1(11):718-9. PubMed ID: 22778808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.
    Higgins GA; Silenieks LB; Lau W; de Lannoy IA; Lee DK; Izhakova J; Coen K; Le AD; Fletcher PJ
    Psychopharmacology (Berl); 2013 Apr; 226(3):475-90. PubMed ID: 23184281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 5-HT
    Campbell EJ; Bonomo Y; Pastor A; Collins L; Norman A; Galettis P; Johnstone J; Lawrence AJ
    Pharmacol Res Perspect; 2021 May; 9(3):e00767. PubMed ID: 33929084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.
    Collins GT; Gerak LR; France CP
    Neuropharmacology; 2018 Nov; 142():63-71. PubMed ID: 29246856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
    Hurren KM; Berlie HD
    Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
    Wacker DA; Miller KJ
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2 new drugs for weight loss.
    Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-HT(2C) receptor agonists and the control of appetite.
    Halford JC; Harrold JA
    Handb Exp Pharmacol; 2012; (209):349-56. PubMed ID: 22249823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Selective 5-HT
    Silenieks LB; Carroll NK; Van Niekerk A; Van Niekerk E; Taylor C; Upton N; Higgins GA
    ACS Chem Neurosci; 2019 Jul; 10(7):3284-3295. PubMed ID: 31082204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats.
    Gannon BM; Sulima A; Rice KC; Collins GT
    J Pharmacol Exp Ther; 2018 Mar; 364(2):359-366. PubMed ID: 29217539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability review of lorcaserin in clinical trials.
    Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
    Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.